This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on clinical hold following the submission of a patient’s safety report. The FDA placed the MELANI-01 trial on hold following the submission of a safety report, according to a Cellectis press release. The safety report...Continue Reading

However, when followed by immunomodulatory drugs, researchers found that autologous stem cell transplant can be safely used in this patient population, regardless of CHIP status. Study findings from investigators at the Dana-Farber Cancer Institute indicated that in patients with multiple myeloma treated with autologous stem cell transplant (ASCT), the presence of clonal hematopoiesis of indeterminate...Continue Reading

This article was originally published by Healio Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly bortezomib and dexamethasone for pretreated multiple myeloma, according to results presented during the ASCO20 Virtual Scientific Program. Findings from the randomized phase 3 BOSTON study showed prolonged PFS and a higher objective response rate in the experimental group....Continue Reading

This article was originally published by AJMC There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to meaningful advances in the therapy of multiple myeloma. However, investigators will first need to clear a number of key hurdles. Chimeric antigen receptor (CAR) gene-modified T-cell therapy appears to have considerable promise for patients with multiple...Continue Reading

This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple myeloma. Although stem cell mobilization is successful in the majority of patients with multiple myeloma, the use of granulocyte colony-stimulating factor (G-CSF) used alone is associated with up to a 10% failure rate, Kumar explains....Continue Reading

First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according to data from a Phase 3 trial. “There is a strong need for additional maintenance treatments for multiple myeloma, where currently approved options are limited,” Meletios Dimopoulos, MD, the trial’s...Continue Reading

This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment regimen combining Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone on the Pharmaceutical Benefits Scheme (PBS). Known as triplet therapy, each drug in the combination has a different mechanism of action to kill myeloma cells, and all work...Continue Reading

Background | Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infusion-related reactions are common. Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this study (COLUMBA), we tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab. Methods...Continue Reading

GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have unveiled the first in silico multiple myeloma patient. Called Gemini, the in silico multiple myeloma patient is a computer model of disease progression and drug response at the individual patient level. The company says Gemini has multiple...Continue Reading

A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.Continue Reading